Proceedings of the National Academy of Sciences · 31 July 2026 · From issue 15
High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
Blocking antibodies in myasthenia gravis patients raised the risk of severe COVID pneumonia up to 12 times.
Adrian Gervais, Astrid Marchal et al.
People with a nerve and muscle disease called myasthenia gravis sometimes make antibodies that block the body's early virus defenses. In a study of 85 unvaccinated people with this disease who caught the coronavirus, those blocking antibodies raised the risk of severe, oxygen-robbing pneumonia several times over. People with a tumor in the thymus gland were more likely to have these antibodies. They were also more likely to get severe pneumonia.
Integrity screen: passed (3 checks) Checked 3 August 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue